title: Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Naratriptan Long-Term Study Group.
abstract: OBJECTIVE
  This open-label study was conducted to evaluate the tolerability and efficacy of the 5HT1 agonist naratriptan with repeated use in the acute treatment of migraine attacks for 1 year. Four hundred and seventeen (417) migraine patients treated 15,301 migraine attacks over the course of the study.
  
  
  RESULTS
  The results show that 84% of attacks treated with a single 2.5 mg dose of naratriptan were not associated with the occurrence of an adverse event. The percentage of attacks associated with an adverse event did not increase with number of doses used to treat a given attack (1 vs. 2) or duration of use (0-6 months vs. > 6-12 months). The only adverse events experienced in > 2% of attacks throughout the 1-year study were nausea (3% of attacks), hyposalivation (2% of attacks), and drowsiness/sleepiness (2% of attacks). Headache relief 4 h post-dose was reported in a median 70% of moderate or severe attacks and a median 86% of mild attacks treated with naratriptan tablets 2.5 mg. The percentages of patients reporting headache relief did not diminish as a function of increased duration of treatment (0-6 months vs. > 6-12 months) or frequency of use (for > 36 vs. < 36 attacks). The mean number of tablets taken per attack was 1.2. A second naratriptan 2.5 mg tablet was taken for headache recurrence in a mean 16% (median 8%) of attacks.
  
  
  CONCLUSIONS
  The results of this study demonstrate that naratriptan tablets 2.5 mg taken for acute migraine attacks over a 1-year period are well-tolerated and effective.
authors.affiliation: Department of Neurology, Austin & Repatriation Medical Centre, Heidelberg, Victoria, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Heywood
authors.forename: M A
authors.initials: MA
authors.lastname: Bomhof
authors.forename: A
authors.initials: A
authors.lastname: Pradalier
authors.forename: L
authors.initials: L
authors.lastname: Thaventhiran
authors.forename: P
authors.initials: P
authors.lastname: Winter
authors.forename: H
authors.initials: H
authors.lastname: Hassani
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D017060:Patient Satisfaction; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D019233:Retreatment; D016879:Salvage Therapy; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013607:Tablets; D013997:Time Factors; D014363:Tryptamines
chemical_list: D007211:Indoles; D010880:Piperidines; D017366:Serotonin Receptor Agonists; D013607:Tablets; D014363:Tryptamines; C106783:naratriptan